Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR)
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
American Society of Hematology
2016
|
| _version_ | 1797090474371055616 |
|---|---|
| author | Doehner, H Vyas, P Seymour, JF Santini, V Stone, RM Minden, MD Al-Ali, HK Del Castillo, TB Morrill, J Songer, S Weaver, J Skikne, BS Beach, CL Dombret, H |
| author_facet | Doehner, H Vyas, P Seymour, JF Santini, V Stone, RM Minden, MD Al-Ali, HK Del Castillo, TB Morrill, J Songer, S Weaver, J Skikne, BS Beach, CL Dombret, H |
| author_sort | Doehner, H |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T03:19:08Z |
| format | Conference item |
| id | oxford-uuid:b6d443b7-e9f2-422b-8f6d-de859409e9d2 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T03:19:08Z |
| publishDate | 2016 |
| publisher | American Society of Hematology |
| record_format | dspace |
| spelling | oxford-uuid:b6d443b7-e9f2-422b-8f6d-de859409e9d22022-03-27T04:43:58ZAzacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR)Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:b6d443b7-e9f2-422b-8f6d-de859409e9d2Symplectic Elements at OxfordAmerican Society of Hematology2016Doehner, HVyas, PSeymour, JFSantini, VStone, RMMinden, MDAl-Ali, HKDel Castillo, TBMorrill, JSonger, SWeaver, JSkikne, BSBeach, CLDombret, H |
| spellingShingle | Doehner, H Vyas, P Seymour, JF Santini, V Stone, RM Minden, MD Al-Ali, HK Del Castillo, TB Morrill, J Songer, S Weaver, J Skikne, BS Beach, CL Dombret, H Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR) |
| title | Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR) |
| title_full | Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR) |
| title_fullStr | Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR) |
| title_full_unstemmed | Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR) |
| title_short | Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR) |
| title_sort | azacitidine aza prolongs overall survival in older patients with acute myeloid leukemia aml with poor prognostic karyotypes compared with conventional care regimens ccr |
| work_keys_str_mv | AT doehnerh azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT vyasp azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT seymourjf azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT santiniv azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT stonerm azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT mindenmd azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT alalihk azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT delcastillotb azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT morrillj azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT songers azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT weaverj azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT skiknebs azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT beachcl azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr AT dombreth azacitidineazaprolongsoverallsurvivalinolderpatientswithacutemyeloidleukemiaamlwithpoorprognostickaryotypescomparedwithconventionalcareregimensccr |